Skip to main content

Table 2 In vivo efficacy of DOX-SLN and free doxycycline against B. melitensis in chronic phase

From: Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study

TreatmentChronic stage
CFUs (Log10) in spleenLog CFUs reductionCFUs (Log10) in liverLog CFUs reduction
Untreated4.96 ± 0.090.004.96 ± 0.010.00
Free SLN4.94 ± 0.100.024.95 ± 0.120.01
DOX-SLN3.51 ± 0.901.45*3.55 ± 0.831.41*
Free doxycycline3.67 ± 0.121.29*3.68 ± 0.741.28*
  1. Comparisons were performed between all treatments and control without treatment: * P < 0.05